<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39411538</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1948-5875</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>ACS medicinal chemistry letters</Title><ISOAbbreviation>ACS Med Chem Lett</ISOAbbreviation></Journal><ArticleTitle>Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum Adsorption.</ArticleTitle><Pagination><StartPage>1677</StartPage><EndPage>1684</EndPage><MedlinePgn>1677-1684</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsmedchemlett.4c00200</ELocationID><Abstract><AbstractText>Toll-like receptor (TLR)-7/8 agonists are promising candidates for the development of new-generation vaccine adjuvants. Adsorption of TLR7/8 agonists on aluminum salts (alum) may further enhance vaccine immunogenicity. Evaluation of the adjuvanticity of the most active dual TLR7/8 agonists, 1-(3-(aminomethyl)benzyl)-2-butyl-1<i>H</i>-imidazo[4,5-<i>c</i>]quinolin-4-amine (<i>m</i>-AM-BBIQ, <b>10</b>) and its <i>para</i> derivative <i>p</i>-AM-BBIQ (<b>11</b>), along with their gallic acid and protocatechuic acid amides in a recombinant-protein-based COVID-19 vaccine platform confirmed the importance of <i>vic</i>-polyphenolic functionality in TLR7/8 agonists for the alum adsorption, thereby resulting in a balanced Th1/Th2 immune response. A novel 7,8-dihydroxy-IMDQ derivative (dh-<i>p</i>-AM-BBIQ, <b>21</b>) was designed wherein the <i>vic</i>-diphenolic functionality was introduced in the quinoline ring of the imidazo[4,5-<i>c</i>]quinoline scaffold. Compound <b>21</b> not only retained the TLR7 agonistic activity (EC<sub>50</sub> = 3.72 μM) but also showed high adsorption to alum and induced a potent antibody response to SARS-CoV-2 spike protein and hepatitis B surface antigen immunized mice. The combination adjuvant comprising compound <b>21</b> adsorbed to alum represents a promising candidate for further development as a human and veterinary vaccine adjuvant.</AbstractText><CopyrightInformation>© 2024 American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Kushvinder</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda-Okubo</LastName><ForeName>Yoshikazu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Vaxine Pty Ltd, 11 Walkley Avenue, Warradale, South Australia 5046, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Respiratory and Sleep Medicine Institute, Bedford Park, South Australia 5042, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakala</LastName><ForeName>Isaac G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Vaxine Pty Ltd, 11 Walkley Avenue, Warradale, South Australia 5046, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Respiratory and Sleep Medicine Institute, Bedford Park, South Australia 5042, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Kamal Nain</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovsky</LastName><ForeName>Nikolai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vaxine Pty Ltd, 11 Walkley Avenue, Warradale, South Australia 5046, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Respiratory and Sleep Medicine Institute, Bedford Park, South Australia 5042, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials (NICOVIA), Panjab University, Chandigarh 160014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salunke</LastName><ForeName>Deepak B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0002-1241-9146</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials (NICOVIA), Panjab University, Chandigarh 160014, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Med Chem Lett</MedlineTA><NlmUniqueID>101521073</NlmUniqueID><ISSNLinking>1948-5875</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39411538</ArticleId><ArticleId IdType="pmc">PMC11472459</ArticleId><ArticleId IdType="doi">10.1021/acsmedchemlett.4c00200</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ten great public health achievements—United States, 1900–1999. Morb. Mortal. Wkly. Rep. 1999, 48 (12), 241–243.</Citation><ArticleIdList><ArticleId IdType="pubmed">10220250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten great public health achievements—worldwide, 2001–2010. Morb. Mortal. Wkly. Rep. 2011, 60 (24), 814–818.</Citation><ArticleIdList><ArticleId IdType="pubmed">21697806</ArticleId></ArticleIdList></Reference><Reference><Citation>Barman S.; Soni D.; Brook B.; Nanishi E.; Dowling D. J. Precision Vaccine Development: Cues From Natural Immunity. Front. Immunol. 2022, 12, 66221810.3389/fimmu.2021.662218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.662218</ArticleId><ArticleId IdType="pmc">PMC8866702</ArticleId><ArticleId IdType="pubmed">35222350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhurani V.; Mohankrishnan A.; Morrot A.; Dalai S. K. Developing effective vaccines: Cues from natural infection. Int. Rev. Immunol. 2018, 37 (5), 249–265. 10.1080/08830185.2018.1471479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2018.1471479</ArticleId><ArticleId IdType="pubmed">29927676</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z.; Liu K. Overview of vaccine adjuvants. Med. Drug Discovery 2021, 11, 10010310.1016/j.medidd.2021.100103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medidd.2021.100103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho N. I.; Huis in ’t Veld L. G. M.; Raaijmakers T. K.; Adema G. J. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?. Front. Immunol. 2018, 9, 2874.10.3389/fimmu.2018.02874.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02874</ArticleId><ArticleId IdType="pmc">PMC6300500</ArticleId><ArticleId IdType="pubmed">30619259</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B.; Arunachalam P. S.; O’Hagan D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discovery 2021, 20 (6), 454–475. 10.1038/s41573-021-00163-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00163-y</ArticleId><ArticleId IdType="pmc">PMC8023785</ArticleId><ArticleId IdType="pubmed">33824489</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda-Okubo Y.; Antipov A.; Andre G.; Barati S.; Kafi H.; Petrovsky N. Ability of SpikoGen®, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants. Immunology 2023, 170 (2), 193–201. 10.1111/imm.13661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13661</ArticleId><ArticleId IdType="pmc">PMC10524547</ArticleId><ArticleId IdType="pubmed">37199229</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Neill L. A.; Golenbock D.; Bowie A. G. The history of Toll-like receptors - redefining innate immunity. Nat. Rev. Immunol. 2013, 13 (6), 453–460. 10.1038/nri3446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3446</ArticleId><ArticleId IdType="pubmed">23681101</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayesh M. E. H.; Kohara M.; Tsukiyama-Kohara K. TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview. Front. Microbiol. 2023, 14, 1249718.10.3389/fmicb.2023.1249718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2023.1249718</ArticleId><ArticleId IdType="pmc">PMC10764465</ArticleId><ArticleId IdType="pubmed">38179453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynn G. M.; Chytil P.; Francica J. R.; Lagová A.; Kueberuwa G.; Ishizuka A. S.; Zaidi N.; Ramirez-Valdez R. A.; Blobel N. J.; Baharom F.; Leal J.; Wang A. Q.; Gerner M. Y.; Etrych T.; Ulbrich K.; Seymour L. W.; Seder R. A.; Laga R. Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction. Biomacromolecules 2019, 20 (2), 854–870. 10.1021/acs.biomac.8b01473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biomac.8b01473</ArticleId><ArticleId IdType="pubmed">30608149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur A.; Baldwin J.; Brar D.; Salunke D. B.; Petrovsky N. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr. Opin Chem. Biol. 2022, 70, 10217210.1016/j.cbpa.2022.102172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbpa.2022.102172</ArticleId><ArticleId IdType="pubmed">35785601</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur A.; Kaushik D.; Piplani S.; Mehta S. K.; Petrovsky N.; Salunke D. B. TLR2 Agonistic Small Molecules: Detailed Structure-Activity Relationship, Applications, and Future Prospects. J. Med. Chem. 2021, 64 (1), 233–278. 10.1021/acs.jmedchem.0c01627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01627</ArticleId><ArticleId IdType="pubmed">33346636</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan D. C.; Herschke F.; Khamlichi M. D.; Rosauro M. L.; Benedicto S. M. P.; Pauwels F.; Stoops B.; Pande V.; Scholliers A.; Van Schoubroeck B.; Mostmans W.; Van Dijck K.; Thoné T.; Horton H.; Fanning G.; Jonckers T. H. M.; Raboisson P. Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists. Bioorg. Med. Chem. Lett. 2018, 28 (19), 3216–3221. 10.1016/j.bmcl.2018.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2018.08.015</ArticleId><ArticleId IdType="pubmed">30143425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik D.; Dhingra S.; Patil M. T.; Piplani S.; Khanna V.; Honda-Okubo Y.; Li L.; Fung J.; Sakala I. G.; Salunke D. B.; Petrovsky N. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant. Hum. Vaccines Immunother. 2020, 16 (8), 1989–1996. 10.1080/21645515.2019.1710409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1710409</ArticleId><ArticleId IdType="pmc">PMC7482670</ArticleId><ArticleId IdType="pubmed">32298200</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilakos J. P.; Tomai M. A. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev. Vaccines 2013, 12 (7), 809–819. 10.1586/14760584.2013.811208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2013.811208</ArticleId><ArticleId IdType="pubmed">23885825</ArticleId></ArticleIdList></Reference><Reference><Citation>Heil F.; Hemmi H.; Hochrein H.; Ampenberger F.; Kirschning C.; Akira S.; Lipford G.; Wagner H.; Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303 (5663), 1526–1529. 10.1126/science.1093620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1093620</ArticleId><ArticleId IdType="pubmed">14976262</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik D.; Kaur A.; Petrovsky N.; Salunke D. B. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. RSC Med. Chem. 2021, 12 (7), 1065–1120. 10.1039/D1MD00031D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1MD00031D</ArticleId><ArticleId IdType="pmc">PMC8292987</ArticleId><ArticleId IdType="pubmed">34355178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik D.; Granato J. T.; Macedo G. C.; Dib P. R. B.; Piplani S.; Fung J.; da Silva A. D.; Coimbra E. S.; Petrovsky N.; Salunke D. B. Toll-like receptor-7/8 agonist kill Leishmania amazonensis by acting as pro-oxidant and pro-inflammatory agent. J. Pharm. Pharmacol. 2021, 73 (9), 1180–1190. 10.1093/jpp/rgab063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpp/rgab063</ArticleId><ArticleId IdType="pmc">PMC8359742</ArticleId><ArticleId IdType="pubmed">33940589</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A. K.; Phatak S. R.; Singh R.; Bhattacharjee K.; Singh N. K.; Gupta A.; Sharma A. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)®) and BBV-152 (Covaxin(TM)®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine 2021, 39 (44), 6492–6509. 10.1016/j.vaccine.2021.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.09.055</ArticleId><ArticleId IdType="pmc">PMC8461292</ArticleId><ArticleId IdType="pubmed">34600747</ArticleId></ArticleIdList></Reference><Reference><Citation>David S. A.Vaccine Adjuvants. WO 2021/226088 A1, 2021.</Citation></Reference><Reference><Citation>Desai D.; Khan A. R.; Soneja M.; Mittal A.; Naik S.; Kodan P.; Mandal A.; Maher G. T.; Kumar R.; Agarwal A.; Gowda N. R.; H V.; Kumar P.; Pandey S.; Pandey R. M.; Kumar A.; Ray A.; Jorwal P.; Nischal N.; Choudhary A.; Brijwal M.; Madan K.; Lodha R.; Sinha S.; Dar L.; Wig N.; Guleria R. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Lancet Infect. Dis. 2022, 22 (3), 349–356. 10.1016/S1473-3099(21)00674-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00674-5</ArticleId><ArticleId IdType="pmc">PMC8610201</ArticleId><ArticleId IdType="pubmed">34826383</ArticleId></ArticleIdList></Reference><Reference><Citation>Vadrevu K. M.; Reddy S.; Jogdand H.; Ganneru B.; Mirza N.; Tripathy V. N.; Singh C.; Khalatkar V.; Prasanth S.; Rai S.; Ella R.; Blackwelder W.; Prasad S.; Ella K. Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study. Lancet Infect. Dis. 2022, 22 (9), 1303–1312. 10.1016/S1473-3099(22)00307-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00307-3</ArticleId><ArticleId IdType="pmc">PMC9212880</ArticleId><ArticleId IdType="pubmed">35717995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik D.; Kaur A.; Patil M. T.; Sihag B.; Piplani S.; Sakala I.; Honda-Okubo Y.; Ramakrishnan S.; Petrovsky N.; Salunke D. B. Structure-Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist. J. Med. Chem. 2024, 67, 8346.10.1021/acs.jmedchem.4c00464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.4c00464</ArticleId><ArticleId IdType="pubmed">38741265</ArticleId></ArticleIdList></Reference><Reference><Citation>Han G.; Tamaki M.; Hruby V. J. Fast, efficient and selective deprotection of the tert-butoxycarbonyl (Boc) group using HCl/dioxane (4 m). J. Pept. Res. 2001, 58 (4), 338–341. 10.1034/j.1399-3011.2001.00935.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-3011.2001.00935.x</ArticleId><ArticleId IdType="pubmed">11606219</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla N. M.; Mutz C. A.; Ukani R.; Warshakoon H. J.; Moore D. S.; David S. A. Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7. Bioorg. Med. Chem. Lett. 2010, 20 (22), 6384–6386. 10.1016/j.bmcl.2010.09.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2010.09.093</ArticleId><ArticleId IdType="pmc">PMC2957514</ArticleId><ArticleId IdType="pubmed">20933417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathi L.; Van Haren S.; Dowling D. J.; Bergelson I.; Shukla N. M.; Malladi S. S.; Balakrishna R.; Tanji H.; Ohto U.; Shimizu T.; David S. A.; Levy O. The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes. PLoS One 2015, 10 (8), e013464010.1371/journal.pone.0134640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0134640</ArticleId><ArticleId IdType="pmc">PMC4537157</ArticleId><ArticleId IdType="pubmed">26274907</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L.; Honda-Okubo Y.; Huang Y.; Jang H.; Carlock M. A.; Baldwin J.; Piplani S.; Bebin-Blackwell A. G.; Forgacs D.; Sakamoto K.; Stella A.; Turville S.; Chataway T.; Colella A.; Triccas J.; Ross T. M.; Petrovsky N. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine 2021, 39 (40), 5940–5953. 10.1016/j.vaccine.2021.07.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.07.087</ArticleId><ArticleId IdType="pmc">PMC8328570</ArticleId><ArticleId IdType="pubmed">34420786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar K.; Sihag B.; Patil M. T.; Singh R.; Sakala I. G.; Honda-Okubo Y.; Singh K. N.; Petrovsky N.; Salunke D. B. Design and Synthesis of Polyphenolic Imidazo[4,5-c]quinoline Derivatives to Modulate Toll Like Receptor-7 Agonistic Activity and Adjuvanticity. ACS Pharmacol. Transl. Sci. 2024, 7, 2063.10.1021/acsptsci.4c00163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.4c00163</ArticleId><ArticleId IdType="pmc">PMC11249636</ArticleId><ArticleId IdType="pubmed">39022355</ArticleId></ArticleIdList></Reference><Reference><Citation>Šileikytė J.; Devereaux J.; de Jong J.; Schiavone M.; Jones K.; Nilsen A.; Bernardi P.; Forte M.; Cohen M. S. Second-Generation Inhibitors of the Mitochondrial Permeability Transition Pore with Improved Plasma Stability. ChemMedChem 2019, 14 (20), 1771–1782. 10.1002/cmdc.201900376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201900376</ArticleId><ArticleId IdType="pubmed">31423734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsueh N.; Chai C. L. L. Evaluation of 2-Bromoisobutyryl Catechol Derivatives for Atom Transfer Radical Polymerization-Functionalized Polydopamine Coatings. Langmuir 2021, 37 (29), 8811–8820. 10.1021/acs.langmuir.1c01143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.langmuir.1c01143</ArticleId><ArticleId IdType="pubmed">34270891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>